CLGN
NASDAQ · Biotechnology
Collplant Biotechnologies Lt
$0.52
-0.07 (-12.54%)
Financial Highlights (FY 2026)
Revenue
711.8K
Net Income
-22,934,570
Gross Margin
-160.0%
Profit Margin
-3,225.1%
Rev Growth
-68.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -160.0% | -160.0% | 47.9% | 47.9% |
| Operating Margin | -3,349.7% | -3,014.7% | 8.0% | 9.0% |
| Profit Margin | -3,225.1% | -3,063.8% | 7.0% | 6.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 711.8K | 2.22M | 1.91M | 2.00M |
| Gross Profit | -1,138,819 | -3,553,257 | 913.8K | 957.4K |
| Operating Income | -23,841,962 | -66,950,907 | 152.5K | 179.9K |
| Net Income | -22,934,570 | -64,402,848 | 134.3K | 123.6K |
| Gross Margin | -160.0% | -160.0% | 47.9% | 47.9% |
| Operating Margin | -3,349.7% | -3,014.7% | 8.0% | 9.0% |
| Profit Margin | -3,225.1% | -3,063.8% | 7.0% | 6.2% |
| Rev Growth | -68.0% | -68.0% | +10.4% | -4.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 2.78M | 2.74M |
| Total Equity | — | — | 7.05M | 7.15M |
| D/E Ratio | — | — | 0.39 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -22,411,029 | -66,428,947 | 222.2K | 203.5K |
| Free Cash Flow | — | — | 168.1K | 175.1K |